The first biological receptor that alerts the immune system to ‘dangerous’ or abnormal cell death has been discovered according to research published in Nature today.
Cell death is a normal process and essential for keeping tissue healthy. But sometimes cells undergo an abnormal form of death – called necrosis – in response to a trauma or injury.
It has long been suspected that sensing this type of cell death could kick-start an immune response because an injury could be accompanied by an infection. But, until now, a receptor with this function had not been found.
The discovery of a ‘danger receptor’ could improve understanding of how immune cells work and help cancer drug discovery; allowing drugs to be targeted so that tumours alert this sensor.
In addition to infections, some tumours could trigger this type of immune reaction, because tumours often have clusters of cells undergoing abnormal cell death at their core as they feed off a limited blood supply. This immune reaction helps the body fight cancer cells.
Dr Caetano Reis e Sousa, lead author based at Cancer Research UK’s London Research Institute, said: “After a 15 year hunt, we’ve identified the first ‘danger receptor’ – one which senses abnormal cell death and then triggers an immune response.
“The detection of ‘danger’ could explain some situations when a tumour triggers an immune reaction against itself.”
The receptor, called DNGR-1, is found on dendritic cells. Dendritic cells are messengers that instruct other immune cells – known as T cells – to attack foreign invaders.
Dr Lesley Walker, Cancer Research UK’s director of cancer information, said: “The concept of using the body’s immune system to fight cancer has been around for decades, but advances in recent years have made this field of research a very exciting one.
“The results of this study are really important scientifically and a step towards understanding how to manipulate the immune system to treat cancer in the future.”
More ecancer oncology news here
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.